

IN THE COURT OF LD. CMM, PATIALA HOUSE COURTS, NEW DELHI
CRIMINAL COMPLAINT NO. _____ OF 2020

IN THE MATTER OF :

Tushar Anand

Vs.

State & Ors.

PS Vasant Vihar

URGENCY APPLICATION

Most Respectfully Showeth:

1. Because the police cannot avoid their duty of registering the FIR if cognizable offence is disclosed
2. Because Registration of FIR is mandatory under Section 154 of the Code, if the information discloses commission of a cognizable offence and no preliminary inquiry is permissible in such a situation.
3. Because the police has failed to take necessary action against the accused persons upon receipt of the complaint.
4. Because the police has failed to register the FIR against the accused persons as per the settled law in **Lalita Kumari Vs. Govt of U.P & Ors.**” 2014 2 SCC-1 held by Hon’ble Apex Court.
5. Because the accused persons cannot escape the rule of law by making a ‘U’ turn from their false representation to the public at large.
6. Because the police just to please their political idols and political masters had failed to register FIR against the accused persons.

Prayed accordingly.

Applicant/Complainant

Place: New Delhi

Dated: 01.07.2020

Through

Lalit Valecha & Manu Prabhakar,
(Advocates)

IN THE COURT OF LD. CMM, PATIALA HOUSE COURTS,
NEW DELHI

CRIMINAL COMPLAINT NO. _____ OF 2020

IN THE MATTER OF:

Tushar Anand

Vs.

State & Ors.

PS Vasant Vihar

INDEX

SR. NO.	PARTICULARS	PAGE NO.
1.	MEMO OF PARTIES	1-2
2.	COMPLAINT UNDER SECTION 156 (3) CR.P.C. ALONGWITH SUPPORTING AFFIDAVIT	3-15
3.	ANNEXURE C-1 News article of Hindustan Times dated 23.06.2020 with the headline - 'Ramdev's Patanjali claims to have Covid - 19 medicine, 100% recovery in 7 days	16-17
4.	ANNEXURE C-2 News article of 'the print.in' dated 24.06.2020 stating AYUSH ministry has asked Patanjali Ayurved to stop advertising	18
5.	ANNEXURE C-3 News article published in Indian Express dated 25.06.2020 with the headline "Ramdev Ayurvedic 'Corona kit': no govt nod"	19-22
6.	ANNEXURE C-4 Copy of complaint dated 24.06.2020	23-25

	filed by the complainant in PS Vasant Vihar	
7.	ANNEXURE C-5 Copy of email dated 24.06.2020 sent to DCP South-West, Delhi Police	26-27
8.	VAKALATNAMA	28

Place: New Delhi
Dated: 01.07.2020

Applicant/Complainant

Through 

Lalit Valecha & Manu Prabhakar,
(Advocates)

6. M/s Patanjali Ayurved Limited
Through its Directors

2

Registered Off:

D-26, Pushpanjali Bijwasan, New Delhi-110061

... Accused Persons

Applicant/Complainant

Place: New Delhi

Dated: 01.07.2020

Through

Lalit Valecha & Manu Prabhakar,
(Advocates)



3

IN THE COURT OF LD. CMM, PATIALA HOUSE COURTS,
NEW DELHI

CRIMINAL COMPLAINT NO. OF 2020

IN THE MATTER OF:

Tushar Anand

Vs.

State & Ors.

Police Station: Vasant Vihar

COMPLAINT ON BEHALF OF THE
COMPLAINANT/APPLICANT UNDER SECTION 156(3) OF
THE CRIMINAL PROCEDURE CODE 1973 SEEKING
DIRECTIONS TO THE STATION HOUSE OFFICER OF THE
POLICE STATION VASANT VIHAR TO REGISTER AND
LODGE FIR AGAINST THE ACCUSED PERSONS UNDER
THE RELEVANT PROVISIONS OF INDIAN PENAL CODE
1860, THE DRUGS AND MAGIC REMEDIES
(OBJECTIONABLE ADVERTISEMENTS) ACT, 1954 AND THE
DRUGS AND COSMETICS ACT, 1940

MOST RESPECTFULLY SHOWETH:

1. That the Applicant is a practicing advocate and is a law abiding citizen of India having full faith in the process of administration of justice by the Court of law.
2. That the Applicant/Complainant watched the press conference of the above said accused persons on television

4
and on social media on 23.06.2020 claiming that they have developed a medicine namely "**Coronil**" which fully cures a patient suffering from Novel Corona Virus (Covid-19). Copy of News article of Hindustan Times dated 23.06.2020 with the headline - 'Ramdev's Patanjali claims to have Covid - 19 medicine, 100% recovery in 7 days is attached herewith and marked as ANNEXURE C-1.

3. That the above named accused persons, acting jointly in in a pre planned conspiracy, are taking undue advantage of their public presence/special status in the society and are making claims stating that they have found a sure shot cure of the Covid - 19 virus.

4. That it is pertinent to mention that the above named accused persons only had permission to make/produce an immunity booster and they are falsely representing/making a false claim in the media via press conference that they have found a cure for the Novel Corona Virus (Covid-19). Copy of News article of 'the print.in' dated 24.06.2020 stating AYUSH ministry has asked Patanjali Ayurved to stop advertising is attached herewith and marked as ANNEXURE C-2.

5

5. That the above named accused persons are taking undue advantage of media and have made a false representation to the people who will buy the product since, the above said accused persons are claiming it to cure the said the deadly corona virus.
6. That by virtue of this the above named accused persons in a pre planned hatched conspiracy with malafide intentions to cause wrongful loss to the public at large by making such mis-representations and with intention to cause wrongful gain to themselves and also producing a product for which they never claimed/received a license by the concerned authorities.
7. That by virtue of their claims pertaining to the said medicine "Coronil", the above said accused persons have shown their malafide intentions which is likely to spread infection of disease dangerous to life by misrepresenting & alluring their innocent followers/purchasers and consumers to buy the above said medicine with a belief of getting cured from the deadly Novel Coronavirus COVID-19.
8. That the above mentioned false claims have further caused intentional insult with intent to provoke breach of peace among the society at large.

9. That the above said accused persons are also in violation of AYUSH Ministry's directives dated 21.04.2020, as per which it is mandatory for an institution *"To appraise the Ministry of AYUSH, Government of India about the research and developments"*.
10. That the above said accused persons are in violation of directives against advertisements of false claims of COVID-19 cure. On 24.03.2020, Home Ministry invoked powers under National Disaster Management Act and declared making of false claims with respect of COVID-19 will be a punishable offence. Following this AYUSH Ministry issued directives on 01.04.2020 invoking Section 33(P) of Drugs and Cosmetics Act to stop and prevent publicity and advertisement of AYUSH related claims for COVID-19 treatment in any print, TV, Electronic media and directed the State/UT authorities to take necessary legal action against the persons/agencies involved found in contravention of the above.
11. That the accused persons apparently did not have the Govt nod to conduct trials and to manufacture the Covid - 19 medicine, however, they continued to work in the said direction for reasons best known to them. Copy of News

article published in Indian Express dated 25.06.2020 with the headline "Ramdev Ayurvedic 'Corona kit': no govt nod" is attached herewith and marked as ANNEXURE C-3.

12. That the above said accused persons are also in violation of section 33(E) read with 33(I) of Drugs and Cosmetics Act, 1940 for the offence of "Misbranded Drugs".

THE DRUGS AND COSMETICS ACT, 1940

33E.. Misbranded drugs. – For the purposes of this Chapter, an Ayurvedic, Siddha or Unani drug shall be deemed to be misbranded –

(a) if it is so coloured, coated, powdered or polished that damage is concealed, or if it is made to appear of better or greater therapeutic value than it really is; or

(b) if it is not labelled in the prescribed manner; or

(c) if its label or container or anything accompanying the drug bears any statement, design or device which makes any false claim for the drug or which is false or misleading in any particular.

33-I. Penalty for manufacture, sale, etc., of Ayurvedic, Siddha or Unani drug in contravention of this Chapter. –

Whoever himself or by any other person on his behalf –

(1) manufactures for sale or for distribution, –

[(a) any Ayurvedic, Siddha or Unani drug –

(i) deemed to be misbranded under section 33E,

(ii) deemed to be adulterated under section 33EE, or

(iii) without a valid licence or in violation of any of the conditions thereof, as required under section 33 EEC, shall be punishable with imprisonment for a term which may extend to one year and with fine which shall not be less than twenty thousand rupees or three times the value of the drugs confiscated, whichever is more;]

(b) any Ayurvedic, Siddha or Unani drug deemed to be spurious under section 33EEA, shall be punishable with imprisonment for a term which shall not be less than one year but which may extend to three years and with fine which shall not be less than [fifty thousand rupees or three times the value of the drugs confiscated, whichever is more]: Provided that the Court may, for any adequate and special reasons to be mentioned in the judgment, impose a sentence of imprisonment for a term of less than one year and of fine of less than 4 [fifty thousand rupees or three times the value of the drugs confiscated, whichever is more]; or

[(c) any Ayurvedic, Siddha or Unani drug in contravention of the provisions of any notification issued under section 33EED shall be punishable with imprisonment for a term which may extend to three years and with fine which may extend to fifty thousand rupees or three times the value of the drugs confiscated, whichever is more.]

(2) Contravenes any other provisions of this Chapter or of section 24 as applied by section 33H or any rule made under this Chapter, shall be punishable with imprisonment for a term which may extend to 6 [six months and with fine which shall not be less than ten thousand rupees].

13. That the above said accused persons have also committed offence under The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, whose relevant sections are copied below for ready reference.

**THE DRUGS AND MAGIC REMEDIES
(OBJECTIONABLE ADVERTISEMENTS) ACT, 1954**

4. Prohibition of misleading advertisements relating to drugs. – Subject to the provisions of this Act, no person shall take any part in the publication of any advertisement relating to a drug if the advertisement contains any matters which –

(a) directly or indirectly gives a false impression regarding the true character of the drug; or

(b) makes a false claim for the drug; or

(c) is otherwise false or misleading in any material particular

7. Penalty.—Whoever contravenes any of the provisions of this Act 3 [or the rules made thereunder] shall, on conviction, be punishable –

(a) in the case of the first conviction, with imprisonment which may extend to six months, or with fine, or with both;

(b) in the case of a subsequent conviction, with imprisonment which may extend to one year, or with fine, or with both.

14. That the accused persons are also in contravention of Central governments amendment to Drug and Cosmetic Rules, 2018, (i.e, Rule 170) "Diagnosis, cure, mitigation, treatment, or prevention of any disease, disorder, syndrome or condition can not be advertised.

15. That by doing the above mentioned acts without any authority of law, the accused persons have acted in conspiracy and committed the offence of cheating the innocent public who is already under burden financially and emotionally due to Covid - 19.

16. That it is of utmost importance that a FIR against the above mentioned accused persons be lodged for offences commissioned under sections 270/420/504/120-B/34 of IPC, Section 33-E read with 33-I of The Drugs and Cosmetics Act 1940, Section 4 read with Section 7 of The Drugs and Magic Remedies (Objectionable Advertisements Act), 1954 so that the above said accused persons do not indulge in act

of making false representations to public at large and gain money out of the misery of people.

17. That the applicant/complainant filed a complaint vide reference no. 81710642000431 addressed to SHO, PS Vasant Vihar dated 24.06.2020 addressing his grievances pertaining to the above mentioned issue. Copy of the complaint filed with SHO, PS Vasant Vihar is attached herewith and marked as ANNEXURE C-4.

18. That the applicant/complaint also sent complaint to the District DCP via email at _____ on 24.06.2020. Copy of the email print is attached herewith and marked as ANNEXURE C-5.

19. That as per information available with the applicant/complainant, the police have not taken any action on the complaint of the applicant/complainant, hence the present complaint.

20. That in **Lalita Kumari Vs. Govt of U.P & Ors.** 2014 2 SCC-1 full bench of Apex Court held that:

“Registration of FIR is mandatory under Section 154 of the Code, if the information discloses commission of a cognizable offence and no preliminary inquiry is permissible in such a situation.

If the information received does not disclose a cognizable offence but indicates the necessity for an inquiry, a preliminary inquiry

may be conducted only to ascertain whether cognizable offence is disclosed or not.

If the inquiry discloses the commission of a cognizable offence, the FIR must be registered. In cases where preliminary inquiry ends in closing the complaint, a copy of the entry of such closure must be supplied to the first informant forthwith and not later than one week. It must disclose reasons in brief for closing the complaint and not proceeding further.

The police officer cannot avoid his duty of registering offence if cognizable offence is disclosed. Action must be taken against erring officers who do not register the FIR if information received by him discloses a cognizable offence.

The scope of preliminary inquiry is not to verify the veracity or otherwise of the information received but only to ascertain whether the information reveals any cognizable offence.

As to what type and in which cases preliminary inquiry is to be conducted will depend on the facts and circumstances of each case. The category of cases in which preliminary inquiry may be made are as under:

- a) Matrimonial disputes/ family disputes
- b) Commercial offences
- c) Medical negligence cases
- d) Corruption cases

e) Cases where there is abnormal delay/laches in initiating criminal prosecution, for example, over 3 months delay in reporting the matter without satisfactorily explaining the reasons for delay.

The aforesaid are only illustrations and not exhaustive of all conditions which may warrant preliminary inquiry.

While ensuring and protecting the rights of the accused and the complainant, a preliminary inquiry should be made time bound and in any case it should not exceed 7 days. The fact of such delay and the causes of it must be reflected in the General Diary entry.

Since the General Diary/Station Diary/Daily Diary is the record of all information received in a police station, we direct that all information relating to cognizable offences, whether resulting in registration of FIR or leading to an inquiry, must be mandatorily and meticulously reflected in the said Diary and the decision to conduct a preliminary inquiry must also be reflected, as mentioned above.

21. That the complainant is a permanent resident of Vasant Vihar, Delhi which falls under the jurisdiction of this Hon'ble Court.

22. That no other similar complaint on the same cause of action has been filed/ pending before any other court except this.

PRAYER


14

It is therefore, most respectfully prayed that this Hon'ble court may graciously be pleased to:

1. Allow the present application u/s 156 (3) Cr.P.C. of the complainant and direct The Station House Officer of Police Station Vasant Vihar to register FIR against the accused persons under Sections 270/420/504/120-B/34 of IPC, Section 33-E read with 33-1 of The Drugs and Cosmetics Act 1940, Section 4 read with Section 7 of The Drugs and Magic Remedies (Objectionable Advertisements Act), 1954
2. Pass such order or further orders which this Hon'ble Court may deem fit and proper in the facts and circumstances of the case.

Applicant/Complainant

Place: New Delhi
Dated: 01.07.2020

Through 

Lalit Valecha & Manu Prabhakar,
(Advocates)

15

IN THE COURT OF LD. CMM, PATIALA HOUSE COURTS,
NEW DELHI

CRIMINAL COMPLAINT NO. OF 2020

IN THE MATTER OF:

Tushar Anand Vs. State & Ors.

AFFIDAVIT

I, Tushar Anand do hereby solemnly
affirm and declare as under:

1. That I am the complainant in the above complaint and I am well conversant with the facts & circumstances of the case and competent to swear this affidavit.
2. That the contents of the accompanying application U/S 156 (3) C.R.P.C. has been drafted by my counsel under my instructions and the same has been read over and explained to me in English and in vernacular language known to me, the contents of which are true and may be read as part and parcel of this affidavit as the same are not reproduced herein for the sake of brevity.

DEPONENT

VERIFICATION: -

Verified at New Delhi on this 01st day of July, 2020 that the contents of above affidavit are true and correct to my knowledge and belief and nothing material has been concealed therefrom.

DEPONENT

ANNEXURE-C-1

hindustantimes

india cities coronavirus #WFHLife opinion world cricket entertainment education trending videos tech podcasts health

Coronavirus Outbreak

India statistics

World statistics

Guide by HT

Latest Stories

Live Updates

ADVERTISEMENT

Home / India News / Ramdev's Patanjali claims to have Covid-19 medicine, 100% recovery in 7 days

Ramdev's Patanjali claims to have Covid-19 medicine, 100% recovery in 7 days

The yoga guru's company Patanjali launched 'Coronil and Swasari' and claimed the clinical trials on affected patients have shown 100 per cent favourable results

INDIA Updated: Jun 23, 2020 15:01 IST



HT Correspondent | Edited by Ashutosh Tripathi
Hindustan Times, New Delhi



Yoga guru Ramdev underlined that necessary approvals for conducting the trials of medicine on patients had been taken from competent authorities.
(Photo @pyptaridwar)

17

Not an immunity booster but a cure, claimed yoga guru Baba Ramdev on Tuesday as he unveiled, what he calls, the first ayurvedic medicine against the coronavirus, even as the scientific community the world over is fighting hard to come up with a cure for the highly contagious disease.

The yoga guru's company Patanjali launched 'Coronil and Swasari' and claimed the clinical trials on affected patients have shown 100 per cent favourable results.

"The whole country and the world was waiting for medicine or vaccine for coronavirus. We are proud to announce that the first Ayurvedic, clinically controlled trial based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS," Yoga Guru Ramdev said at a press conference in Hairdwar, adding that it has shown "100 per cent recovery rate within 3-7 days."

"We are launching Covid medicines Coronil and Swasari today. We conducted two trials of these, first clinical controlled study, which took place in Delhi, Ahmedabad, among many other cities. Under this 280 patients were included and 100 per cent of those recovered. We were able to control coronavirus and its complications in this. After this the all-important clinical control trial was conducted," he added.

The Corona kit will be made available at just Rs 545, said Acharya Balkrishna, chief executive officer of Patanjali, adding that the kit is for 30 days.

"This medicine kit is not available anywhere for now and will be made available at Patanjali stores in a week, said Baba Ramdev. He added that an app will be launched for the delivery of the corona kit.

Ramdev underlined that necessary approvals for conducting the trials of medicine on patients had been taken from competent authorities.

Acharya Balkrishna was present at the occasion of the launch with other officials and representatives who had taken part in the preparation of the medicine.

Enter your email to get our daily newsletter in your inbox

Enter email address

tags

18
ANNEXURE - C-2

All about Magic Remedies Act, law that landed Patanjali in trouble over Covid 'cure' drug

Patanjali Ayurved Tuesday launched the 'Coronil and Swasari' medicines with the claim that it has discovered a cure for Covid-19.

APOORVA MANDHANI

24 June, 2020 3:18 pm IST

Advertisement



Baba Ramdev addresses the media during the launch of Coronil tablet for Coronavirus, in Haridwar on 23 June 2020 | ANI

Text Size: A- A+

New Delhi: Hours after yoga guru Baba Ramdev's Patanjali Ayurved launched an Ayurvedic medicine claiming to be a cure for Covid-19 Tuesday, the AYUSH Ministry set into action, asking it to stop advertising such claims.

The statement released by the ministry referred to a notification issued by it on 21 April, listing down the requirements and manner in which research studies can be conducted on Ayurveda, Siddha, Unani and Homeopathy drugs for Covid-19.

Advertisement

In addition, the release also pointed out that such advertisements of Ayurvedic medicines are regulated by the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

THURSDAY, JUNE 25, 2020, NEW DELHI LATE CITY, 18 PAGES

MUST STRICTLY RESPECT AND OBSERVE LAC: INDIA

Diplomats build on military talks: Both need to implement plan on disengagement of troops

Border Affairs group meets as Chinese Defence Ministry asserts Galwan claim


SHUBHAJIT ROY
NEW DELHI, JUNE 24

INDIAN and Chinese diplomats agreed Wednesday to sincerely implement the understanding on disengagement and de-escalation along the Line of Actual Control in Ladakh where both sides have massed troops in a face-off since May.

After a meeting of the Working Mechanism for Consultation and Coordination on India-China Border Affairs (WMCCA) held two days after Corps Commanders of the two armies reached a "mutual consensus to disengage troops, the Indian side conveyed its concerns on the developments in eastern Ladakh, including the June 15 showdown in Galwan Valley in which 20 Indian Army personnel were killed.

The Ministry of External Affairs said it was emphasised that both sides should "strictly respect and observe" the Line of Actual Control.

CONTINUED ON PAGE 2



Satellite images of road construction near Galwan Valley on June 22. Maxar Technologies via Reuters

Satellite catches Chinese structures back at Galwan

KRISHN KAUSHIK
NEW DELHI, JUNE 24

AS INDIA and China held diplomatic and military talks to disengage troops along the Line of Actual Control in eastern Ladakh, new satellite images show that the Chinese have built a defensive position at the Galwan Valley since the June 15 clashes in which 20 Indian Army personnel

not were killed. Top sources in the Army confirmed that the tent which was removed on June 15 has been reported back by our ground troops at PP-14 (Patrolling Point 14). Reached for comment, the Army did not confirm or deny the existence of Chinese structures visible in the satellite images. The images from Maxar, a

CONTINUED ON PAGE 2

Closer to strategic DBO, China opens a new front at Depsang

SUSHANT SINGH
NEW DELHI, JUNE 24

AS INDIA and China grapple with rising tensions in the Galwan Valley, Hot Springs and Pangong Tso on the Line of Actual Control (LAC), the Chinese army has crossed the border in another strategic area to the north, the Depsang Plains. This move is seen as another attempt by the Chinese to shift the LAC further west on the disputed boundary.

Around 30 km south-east from the important airstrip of Daulat Beg Oldie (DBO), the Chinese army has moved and deployed large numbers of troops to a place called Y-junction or Bortleneck. This location is seven kilometres to the north-east of Basse, a Ladakhi town which lies on the 255-km Daulat-Beg Oldie (DBO) road and has an Indian Army post.

When contacted, the Army's media wing declined to comment on the matter, with an officer telling The Indian Express that "the report can neither be confirmed nor denied". Bortleneck is known as Y-junction because the track coming from Bortle forks into two tracks, one going northward along the Rail Nalla to Patrolling Point-10 (PP-10) and the other



THE WORLD

PAK FAILS TERROR TEST, SET TO STAY IN FATF GREY LIST

another five kilometres further west. This location is seven kilometres to the north-east of Basse, a Ladakhi town which lies on the 255-km Daulat-Beg Oldie (DBO) road and has an Indian Army post. When contacted, the Army's media wing declined to comment on the matter, with an officer telling The Indian Express that "the report can neither be confirmed nor denied". Bortleneck is known as Y-junction because the track coming from Bortle forks into two tracks, one going northward along the Rail Nalla to Patrolling Point-10 (PP-10) and the other

CONTINUED ON PAGE 2

Now past Mumbai too at Covid top, Delhi to survey all houses, ramp up testing

ASTHA SAXENA
NEW DELHI, JUNE 24

WITH 3,788 new Covid-19 cases being reported on Tuesday, Delhi has overtaken Mumbai as the city with the highest case count — 70,390 cases so far. The total case count in Mumbai, which reported 1,118 new cases on the last 24 hours, is 69,528.

While Delhi has done 4.2 lakh tests so far (about 22,142 per million), Mumbai 294 lakh tests (22,668 per million). Mumbai's positivity rate (23.2%) remains higher than Delhi (16.7%). Delhi also has fewer deaths (2,365) than Mumbai (3,964). With the number of cases still

rising, the Delhi government has prepared an ambitious plan — house-to-house screening in containment zones by June 30, and in the rest of the city by July 6.

The revised Covid response plan, which places emphasis on active surveillance followed by rigorous testing, was formulated after a high-level panel, led by NITI Aayog member Dr VK Paul, suggested a series of measures to tackle the virus spread.

In a meeting with the chief secretary, district magistrates were asked to form teams by

CONTINUED ON PAGE 2

FULL COVERAGE
PAGE 4

TRACKING INDIA'S COVID CURVE

CUMULATIVE CASES: 4,56,183 RECOVERED: 2,58,064 DEATHS: 14,476 TESTS: 73,52,911 DOWNGRADE: 19.5%

STATE/UT	CUMULATIVE CASES	RECOVERED	DEATHS	TESTS	DOWNGRADE RATE
1. Maharashtra	1,39,010	1,24,416	2,095	24,444	8.50
2. Telangana	9,553	8,791	8,478	8,50	8.50
3. Delhi	66,602	3,947	5,878	12,27	16.67
4. Tamil Nadu	64,603	2,516	4,338	16,67	16.67
5. Karnataka	11,520	495	4,855	14,85	14.85
6. West Bengal	14,728	370	3,088	23.36	23.36

* Compounded Daily Growth Rate over last 7 days. ** Calculated over 7-day growth

CONCERN
DELHI: With rising up cases to more than 4,000 on Tuesday — single-day max for any state

CAUTION
PUNJAB: State witnessing a resurgence. More than 1,000 cases last week

A GLIMMER
UP: Slower in last one week but still growing faster than national average

Based on daily data by Centre for COVID, state governments

INSIDE

KAUNAIN SHERIFF & DEEP MUKHERJEE
NEW DELHI, JAIPUR, JUNE 24

A DAY AFTER Ramdev launched an ayurvedic 'Corona Kit' claiming it cured Covid-19, serious questions have emerged over the business practices of Patanjali Ayurved Ltd, the Patanjali brand products and Divya Pharmacy, the unit producing the medicines.

On Wednesday, a day after

CONTINUED ON PAGE 2

CABINET ALLOWS PVT SECTOR IN SPACE; CO-OP BANKS NOW UNDER RBI

PAGES 9, 17

THE EDITORIAL PAGE

JUSTICE IN THE TIMES OF PANDEMIC

BY GOVIND KAPOOR

PAGE 5

E-comm firms told: Let buyers know country of origin of goods

PRASHA RAGHAVAN & PRANAV MUKUL

NEW DELHI, JUNE 24

THE DEPARTMENT for Promotion of Industry and Internal Trade (DPIIT) Wednesday directed e-commerce firms to work out a mechanism that will enable customers to identify the country of origin for all products displayed on their platforms. The Indian Express has learnt.

The direction was conveyed during a meeting with representatives of 20 firms, including Amazon, Flipkart, Paytm and Reppertory, following which the platforms sought around 10 days to work out a system, according

CONTINUED ON PAGE 2

A big challenge

THE move could pose complications in case of products with inputs from several countries. Also, e-commerce firms do not own the inventory sold on their platforms, and would need to work out the way forward with a large number of sellers.

Ramdev Ayurvedic 'corona kit': no govt nod, trials that used allopathic drugs

KAUNAIN SHERIFF & DEEP MUKHERJEE
NEW DELHI, JAIPUR, JUNE 24

A DAY AFTER Ramdev launched an ayurvedic 'Corona Kit' claiming it cured Covid-19, serious questions have emerged over the business practices of Patanjali Ayurved Ltd, the Patanjali brand products and Divya Pharmacy, the unit producing the medicines.

On Wednesday, a day after

CONTINUED ON PAGE 2

the Ministry of Ayush ordered Patanjali to stop publishing claims of Covid-19 cure, the Uttar Pradesh government said its licensing authority did not grant any approval to the Corona Kit, and the Rajasthan government told The Indian Express it had no knowledge of clinical trials at National Institute of Medical Sciences and Research (NIMS), a private hospital in Jaipur where Covid-19 patients are admitted. Most significantly, when mildly symptomatic patients

CONTINUED ON PAGE 2

BUSINESS AS USUAL

BY UNNY



SHUBHRA RANJAN

Always Ahead

GS FOUNDATION 2021 TABLET COURSE

PROGRAM FEATURES

Two subjects at a time

Prelims and Mains Test included

Coverage of important issues

Answer writing practice sessions

Prelims MCQ practice

Synchronisation of Syllabus

Value added notes.

Faculty driven test discussions

Test strategy discussion videos.

Timely evaluation of copies.

Classes available on Tablet mode.

COURSES OFFERED

GS Foundation Tablet Course 2021

TOTAL FEE ₹68,700

REGISTER NOW

SCAN HERE FOR COUNSELLING SESSION

*PSIR and Geography optional courses also available

BATCH STARTING 29th JUNE 2020

BATCH TIMING 7:30 P.M. - 10:00 P.M.

LIVE Q&A: 10:15 P.M. - 11:00 P.M.

FOR MORE - CONTACT: +9111-45612719

OUR TOPPERS

delhi@shubhبرانان.com

www.shubhبرانان.com

132-B, Pura Road, Karol Bagh, New Delhi 110005

011-45612719 +919910812719

GLIC Re
General Insurance Corporation of India

Gross Premium

₹ 51,030.13 Cr. ₹ 35,425.87 Cr. 1.53

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2020

Sl. No.	Particulars	2020 Year Ended		2019 Year Ended	
		(Audited)	(Audited)	(Audited)	(Audited)
		March 31, 2020	March 31, 2020	March 31, 2019	March 31, 2019
1	Premium Income (Gross)	51,030.13		44,238.00	
2	Net Profit/(Loss) After Tax	(359.09)		2,224.31	
3	Paid Up Equity Share Capital	877.20		877.20	
4	Net Worth (Including fair value change account)	35,425.87		52,765.05	
5	Total Assets	1,16,196.20		1,18,883.57	
6	Solvency Ratio	1.53		2.06	

Notes:
a) Premium Income is Gross written premium, gross of reinsurance and net of applicable taxes.
b) The above is an extract of the detailed format of quarterly and year to date Financial results filed with the stock exchanges under Regulation 33 and Regulation 52 of SEBI (Listing and Other Disclosure Requirements) Regulations 2015. The full format of the quarterly and year to date Financial results are available on the websites of Stock exchanges (www.bseindia.com HYPERLINK "http://www.bseindia.com/" and www.nseindia.com) and the Corporation (www.glicindia.com).

For and on behalf of the Board Directors

Sd/-
Devesh Srivastava
Chairman-cum-Managing Director

Place: Mumbai
Date: 24th June, 2020

*Surksha, 170, Janshakti Tata Road, Churchgate, Mumbai - 400 020, India • Email: info@glicindia.com • Tel.: +91 22 22867000

CHIN 92000517726000183 www.glicindia.com [ROAT Registration No. 12]

Decoding Congress' targeting of PM Modi, Covid testing to rise

NEWSPERSON EVERYDAY

In today's episode of the 3 Things podcast, we look at why the Congress is going after PM Modi over the Calwan valley faceoff despite it waging a lone battle.

DOWNLOAD APP

- VISUAL STORIES
- DAILY BRIEFING
- PODCASTS
- CUSTOMIZABLE NEWS EXPERIENCE

Indian Express
★★★★ 4.6

SCAN THIS QR CODE TO DOWNLOAD THE APP



VIDEO OF THE DAY

NEWLY-WEDS DONATE 50 BEDS

A newly-wed couple in Mumbai has donated 50 beds to a Covid centre

ENTERTAINMENT

AARYA SHOWCASES SUMMITTANEN

What Sena accomplishes with Aarya she hasn't done before

TARIFF RATE QUOTA SCHEME

Centre notifies norms for import of maize at concessional duty

EXPRESS NEWS SERVICE
NEW DELHI, JUNE 24

AMID SUDDEN prices of maize in the wake of the Covid-19 lockdown, the Centre has notified norms for import of 5 lakh tonnes of maize under Tariff Rate Quota Scheme during the current financial year at a concessional duty of 15 per cent.

At present, maize attracts 50 per cent import duty.

The move may further dampen the hopes of maize farmers, who were expecting prices to rise with pickup in demand after un-lodgement.

Maize farmers in Bihar, who account for over 80 per cent of India's 6-7 million tonnes (mt) of annual production of maize, are facing difficulties in selling their produce.

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

FROM PAGE ONE

Satellite

space technology company, are from June 22 and show that the Chinese have built a defensive position "astride" the LAC near PP-14. The position has been built between June 16 and June 22 because Planet Labs satellite images of the location on June 16, a day after the clashes, do not show any such infrastructure.

On June 20, the Prime Minister's Office, in a statement, had said that "the reports transgression of LAC, it was clearly stated that the violence in Galwan on 15 June arose because Chinese side was seeking to erect structures just across the LAC and refused to desist from such actions."

After analysing the new satellite images, Lt General (ret'd) Al Chavan, who also served as Division Commander of the 3rd Infantry Division, responsible for eastern Ladakh, told The Indian Express "it appears to be a proper defensive position which has been developed by the Chinese".

He said that the Chinese have built a defensive position "astride" the LAC near PP-14. The position has been built between June 16 and June 22 because Planet Labs satellite images of the location on June 16, a day after the clashes, do not show any such infrastructure.

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Under the scheme, the government will procure up to 10,000 tonnes of skimmed milk powder during a fiscal (from the Tariff Rate Quota Scheme).

Diplomats build on military talks: Need to implement plan on disengagement

The Chinese statement mentioned the exchange of "candid and in-depth" views on the border situation and how both sides said they will "actively implement the important consensus" reached by the Foreign Ministers during their June 17 phone conversation, and "actively accommodate with the two military forces to implement the important consensus" reached at the June 6 and June 22 military talks.

The Chinese Defence Ministry, however, struck a jarring note, echoing Beijing's claim to the Galwan Valley.

China has sovereignty over the Galwan Valley region and the Chinese border troops have been patrolling and on duty in this region for many years," it said. This is the first time that the Chinese have claimed to have a claim to an area that is well within Indian territory.

Narens Srivastava, Joint Secretary (East Asia) in the Ministry of External Affairs,

terred negative, in the placebo group, 65 per cent were negative, and remaining 35 per cent continued to test positive for active virus. Patients received Swastika RS (500 mg), pure Ashwagandha extract (500 mg), pure Glyoxy extract (500 mg), pure Tulsi extract (500 mg) and Amritul extract (500 mg).

In Covid research, doctors continuously measure inflammatory markers to monitor the severity of the infection. As part of assessing "secondary outcomes", this study also examined an important inflammatory marker — interleukin-6 (IL-6).

In the placebo group, the response to the immune system in severe patients. Devpara admitted that the reduction in IL-6 was "not statistically significant".

Devpara said that the study was "finally" resolved. Attaching a note by the Ministry of Ayush which acknowledged the receipt of documents of the clinical study and ethical research, Institutional Ethics Committee clearance, registration of the study, sample size and study results data, he said, "The resolution of AYUSH controversy finally."

"Ministry will have the study documents verified for validation of the data of the research outcome," the Drug Policy Section, Ministry of Ayush said.

However, the Uttar Pradesh government's notice to Dnyan Pharmacy and the Rajasthan government's denial that any approval was accorded for conducting the clinical trials, raise serious questions about Patanjali Ayurved's business practices.

In a letter to Dnyan Pharmacy, the Uttar Pradesh Drug Licensing Authority categorically stated that no permission was granted to the firm to manufacture the "corona" in the state.

Patanjali Ayurved, for treating cough and breathlessness, and to the coronal tablet as an "immunity booster, specially against respiratory tract infection and all levers".

Pointing out that the firm had displayed an image of Coronavirus on the tablet, the licensing authority said this was in violation of relevant sections under the provisions of Drugs and Magic Remedies (Objections to Advertisements)

Act, 1954, and asked why action should not be taken to cancel the licence for manufacturing these medicines.

Injunctive, Rohit Kumar Singh, Additional Chief Secretary (Health), told The Indian Express, that the government did not have any knowledge about these trials and did not give any request for authorisation.

"As per due process, the state government is informed before such a trial, and we refer the request to the state's civil trial committee and ethics committee. After getting permission from these committees, we forward the request to the Drug Controller General of India (DCGI) and the Indian Council of Medical Research (ICMR) who give the final approval," he said.

"We had only asymptomatic patients. It can't be said that this particular medicine treated them successfully within a few days," said Dr. Nandini Sharma, Chief Medical Officer, Rajasthan University of Health Sciences, Bikaner.

Rajasthan Health Minister Rajiv Sharma said the clinical trial process was done without following the due process and without informing the government.

"There are no guidelines for clinical trials which weren't followed. During a pandemic threatening the world, this sort of action is absolutely unacceptable," he said.

We were informed before these clinical trials took place despite the fact that tests administered at NIMS are being monitored by the state government. I have instructed officials to take action if any attempt is made to sell this drug as a potential medicine of Covid-19 in Rajasthan," he said.

WALIMUNI SIVOM (WALIMUNI SIVOM, LUCKNOW)

Delhi survey

Friday, which must have a healthcare worker to assess a person's medical condition.

"Now, all households in the city will be surveyed by field workers. Till now, we were carrying out surveillance in containment zones and across various positivity rate was high. Under the revised plan, anyone found with symptoms will be tested," said a senior district official.

A task force comprising representatives of Delhi Police, MCD, district surveillance officials, health officers, and medical colleges and the department of education and youth is to be

set up by each district surveillance unit. The revised strategy also suggests redefining containment zones, which currently stand at 266.

"A 100 household survey has to be carried out by July 6 and all districts have been asked to ramp up work accordingly. The team has to visit each home and note down the health profile of residents. Data has to be uploaded on a portal and if anyone is found to be symptomatic, he or she needs to be tested through antigen testing," said another district official.

The city has been following two strategies for testing — RT-PCR, considered the gold standard for testing, and antigen testing, which is faster. A genotyping, which is used to identify the source of the virus, is soon going to be followed through "sero-surveillance" of 20,000 people.

Top health department officials, along with a team of NDC, are preparing a roadmap for Delhi to carry out sero-surveillance in all 11 districts. This involves collecting blood samples to determine if a person is or was infected with coronavirus.

Sources said a certain number of the population in each district will be randomly tested. "It will be a mix of all age groups, even those below 18. This will help identify the spread of the virus and the number of people who have developed immunity," said a senior health official.

NDC will provide training to district officials on Thursday on how to identify areas for sero-surveillance.

E-commerce firms

Senior officials and executives. Another meeting with the firms is expected to take place soon, possibly within a week or 10 days, to take stock of the measures, executives close to the development said.

Experts say such a requirement does not have a precedent, may not be easy to roll out and may require more brainstorming, especially for products, such as smartphones and laptops, that may have inputs from several countries.

The development comes against the backdrop of the border face-off with China and the central government pushing for self-reliance through Atmanirbhar Bharat campaign. It also follows the Commerce Ministry's announcement Tuesday that sellers on the government e-marketplace (GeM Portal) will have to disclose the

country of origin for products. Wednesday's meeting also involved firms like Tata, Mynta, JioMart, BigBasket and Shoppers' Stop. "It will be difficult to get it rolling with the urgency that the government seemed to be pushing it with because there are thousands of products on our platform," said an e-commerce executive.

Another executive said the responsibility of providing accurate information was with the sellers and not the marketplace, which can only educate them about complying with the law of the land.

The first meeting to understand what exactly they (e-commerce firms) would require, this is very preliminary, because this is the first time we have taken this up with them and they needed some time to assess," said a senior government official.

"More meetings will be held with the platform, but no dates have been fixed. Normally, the most important aspect of any decision is the customer's say here, information becomes a key factor," said the official.

The DPM had called the platform since they needed to work out the modalities through discussions with sellers. Said another senior official, "There is no prohibition or restriction. This is basically to help the customer know whether they are buying a product made in India. If they customise it, on how it can be done," said the official.

According to e-commerce executives, the proposal had been discussed in earlier meetings but the government "seemed insistent" on having it done this time.

Various online retailers have already represented to the DPM that they would need time to finalise technical modalities. And some experts anticipate that the implementation may be "tricky".

"It will be tricky to calculate the value added of a product sold on such a platform. No products have been developed yet for this in the e-commerce space in any country so far, so I'm not sure how it will be done," said Rajat Khatwaria, Director and Chief Executive, Indian Council for Research on International Relations (ICRIER).

The DPM's meeting comes nearly 10 days after the Confederation of All India Traders (CAIT) approached Commerce Minister Piyush Goyal to make the origin mandatory for private e-commerce firms.

The decision would be "crucial" in CAIT's "Boycott Chinese Goods" campaign, the secretary general, Praveen Khandelwal, said. "We are not against Chinese goods, but we are against the government's decision to allow Chinese goods to be sold on various e-commerce portals as Chinese, according to him.

"When the government can implement the decision on GeM portal, why can't the e-commerce companies do it?" said Khandelwal.

New Delhi

India

India

India

India

India

country of origin for products. Wednesday's meeting also involved firms like Tata, Mynta, JioMart, BigBasket and Shoppers' Stop. "It will be difficult to get it rolling with the urgency that the government seemed to be pushing it with because there are thousands of products on our platform," said an e-commerce executive.

Another executive said the responsibility of providing accurate information was with the sellers and not the marketplace, which can only educate them about complying with the law of the land.

The first meeting to understand what exactly they (e-commerce firms) would require, this is very preliminary, because this is the first time we have taken this up with them and they needed some time to assess," said a senior government official.

"More meetings will be held with the platform, but no dates have been fixed. Normally, the most important aspect of any decision is the customer's say here, information becomes a key factor," said the official.

The DPM had called the platform since they needed to work out the modalities through discussions with sellers. Said another senior official, "There is no prohibition or restriction. This is basically to help the customer know whether they are buying a product made in India. If they customise it, on how it can be done," said the official.

According to e-commerce executives, the proposal had been discussed in earlier meetings but the government "seemed insistent" on having it done this time.

Various online retailers have already represented to the DPM that they would need time to finalise technical modalities. And some experts anticipate that the implementation may be "tricky".

"It will be tricky to calculate the value added of a product sold on such a platform. No products have been developed yet for this in the e-commerce space in any country so far, so I'm not sure how it will be done," said Rajat Khatwaria, Director and Chief Executive, Indian Council for Research on International Relations (ICRIER).

The DPM's meeting comes nearly 10 days after the Confederation of All India Traders (CAIT) approached Commerce Minister Piyush Goyal to make the origin mandatory for private e-commerce firms.

The decision would be "crucial" in CAIT's "Boycott Chinese Goods" campaign, the secretary general, Praveen Khandelwal, said. "We are not against Chinese goods, but we are against the government's decision to allow Chinese goods to be sold on various e-commerce portals as Chinese, according to him.

"When the government can implement the decision on GeM portal, why can't the e-commerce companies do it?" said Khandelwal.

New Delhi

India

India

India

India

India

country of origin for products. Wednesday's meeting also involved firms like Tata, Mynta, JioMart, BigBasket and Shoppers' Stop. "It will be difficult to get it rolling with the urgency that the government seemed to be pushing it with because there are thousands of products on our platform," said an e-commerce executive.

Another executive said the responsibility of providing accurate information was with the sellers and not the marketplace, which can only educate them about complying with the law of the land.

The first meeting to understand what exactly they (e-commerce firms) would require, this is very preliminary, because this is the first time we have taken this up with them and they needed some time to assess," said a senior government official.

"More meetings will be held with the platform, but no dates have been fixed. Normally, the most important aspect of any decision is the customer's say here, information becomes a key factor," said the official.

The DPM had called the platform since they needed to work out the modalities through discussions with sellers. Said another senior official, "There is no prohibition or restriction. This is basically to help the customer know whether they are buying a product made in India. If they customise it, on how it can be done," said the official.

According to e-commerce executives, the proposal had been discussed in earlier meetings but the government "seemed insistent" on having it done this time.

Various online retailers have already represented to the DPM that they would need time to finalise technical modalities. And some experts anticipate that the implementation may be "tricky".

"It will be tricky to calculate the value added of a product sold on such a platform. No products have been developed yet for this in the e-commerce space in any country so far, so I'm not sure how it will be done," said Rajat Khatwaria, Director and Chief Executive, Indian Council for Research on International Relations (ICRIER).

The DPM's meeting comes nearly 10 days after the Confederation of All India Traders (CAIT) approached Commerce Minister Piyush Goyal to make the origin mandatory for private e-commerce firms.

The decision would be "crucial" in CAIT's "Boycott Chinese Goods" campaign, the secretary general, Praveen Khandelwal, said. "We are not against Chinese goods, but we are against the government's decision to allow Chinese goods to be sold on various e-commerce portals as Chinese, according to him.

"When the government can implement the decision on GeM portal, why can't the e-commerce companies do it?" said Khandelwal.

New Delhi

India

India

India

India

India

Ramdev Ayurvedic 'corona kit': no govt²¹ nod, trials that used allopathic drugs

**KAUNAIN SHERIFF M &
DEEP MUKHERJEE**
NEW DELHI, JAIPUR, JUNE 24

A DAY AFTER Ramdev launched an ayurvedic 'Corona Kit' claiming it cured Covid-19, serious questions have emerged over the business practices of Patanjali Ayurved Ltd, the FMCG company that markets Patanjali brand products and Divya Pharmacy, the unit producing the medicines.

On Wednesday, a day after

the Ministry of Ayush ordered Patanjali to stop publicising claims of Covid-19 cure, the Uttarakhand government said its licencing authority did not grant any approval to the Corona Kit, and the Rajasthan government told The Indian Express it had no knowledge of clinical trials at National Institute of Medical Sciences and Research (NIMS), a private hospital in Jaipur where Covid-19 patients are admitted.

Most significantly, when mildly symptomatic patients

CONTINUED ON PAGE 2

BUSINESS AS USUAL

By UNNY



tres to the west of the LAC on Indian maps. This 20-km frontage is the only portion on the border where the LoP falls short of LAC. It has been done due to historical reasons, and the LoP has been approved by the China Study Group.

After the 2013 standoff was resolved, India had created a new patrol base at Bottleneck, with a kind of permanent patrol deployed there, to observe and stop any Chinese patrols from moving any further. But a Chinese patrol had still managed to get through to a place around 15 km short of Burtse in September 2015.

As reported earlier, there have been a large number of transgressions by Chinese patrols in the area which have been recorded by the Indian side. There were 157 transgressions in 2019, up from 83 in 2018 and 75 in 2017.

Patanjali trials

developed fever during the trials, they were administered allopathic medicines. As it is, the trials were conducted only on asymptomatic and mildly symptomatic patients. Severely symptomatic patients and those with acute respiratory distress syndrome were excluded for enrolment.

Moreover, the study based on these trials at NIMS, are not peer-reviewed, admitted Dr Ganpat Devpura, Principal Investigator, NIMS, Jaipur.

When contacted, Devpura told The Indian Express, "This is just an interim report with a sample size of 100 Covid-19 patients. The final report and the findings will be published after 15-25 days and then it will be sent for peer review."

When questioned if allopathic medicines were administered to mildly symptomatic patients during the trial when they developed symptoms, Devpura said, "Yes, if patients had developed symptoms like fever, symptomatic treatment was given."

Elaborating on the interim findings of the trial, Devpura said, "It is a double-blind randomised trial. 50 patients were on placebo and the remaining 50 were on active drugs (the Ayurvedic therapy). We did the RT-PCR test on Day 1, Day 3, and Day 7. On Day 3, 69 per cent active patients tested negative; in the placebo group, only 50 per cent were tested negative."

"On Day 7, in the active group, all the remaining patients

tested negative. In the placebo group, 65 per cent were negative, and remaining 35 per cent continued to test positive for Covid-19," Devpura said. In the active group, patients received Swasari Ras (500 mg), pure Ashwagandha extract (500 mg), pure Giloy extract (500 mg), pure Tulsi extract (500 mg) and Anutaila nasal drops.

In Covid treatment, doctors continuously measure inflammatory markers to monitor the severity of the infection. As part of assessing "secondary outcomes", this study too examined an important inflammation marker - Interleukin 6 (IL-6), a cytokine, which shows excessive response on the immune system in severe patients. Devpura admitted that the reduction in IL-6 was "not statistically significant" in active patients during the trial.

Balkrishna, Managing Director, Patanjali Ayurved Ltd, however, claimed the controversy was "finally" resolved. Attaching a note by the Ministry of Ayush which acknowledged the receipt of documents of the clinical trial including site of a clinical study and medical research, Institutional Ethics Committee clearance, registration details of CTRI, study protocol, sample size and study results data, he said. "The resolution of AYUSH controversy finally."

"Ministry will have the study documents verified for validation of the data of the research outcome," the Drug Policy Section, Ministry of Ayush said.

However, the Uttarakhand government's notice to Divya Pharmacy and the Rajasthan government's denial that any approval was accorded for conducting the clinical trials, raise serious questions about Patanjali Ayurved's business practices.

In a letter to Divya Pharmacy, the Uttarakhand Drug Licensing Authority categorically stated that no permission was granted to the firm to manufacture the "corona kit". It said approval was given to Swasari for treating cough and breathlessness and to the coronal tablet as an "immunity booster, specially against respiratory tract infection and all fevers".

Pointing out that the firm had displayed an image of Coronavirus on the tablet, the licensing authority said this was in violation of relevant Sections under the provisions of Drugs and Magic Remedies (Objectionable Advertisements)

Act, 1954, and asked why action should not be taken to cancel the licence for manufacturing these medicines.

In Jaipur, Rohit Kumar Singh, Additional Chief Secretary (Health), told The Indian Express, that the government did not have any knowledge about these trials and did not receive any request for authorisation. "As per due process, the state government is informed before such a trial, and we refer the request to the state's clinical trial committee and ethics committee. After getting permission from these committees, we forward the request to the Drug Controller General of India (DCGI) and the Indian Council of Medical Research (ICMR) who give the final approval," he said.

"NIMS had only asymptomatic patients. It can't be said that this particular medicine treated them successfully within a few days," said Dr Narottam Sharma, Chief Medical Health Officer, Rajasthan University of Health Sciences.

Rajasthan Health Minister Raghu Sharma said the clinical trial process was done without following the due process and without informing the government. "There are clear guidelines for clinical trials which weren't followed. During a pandemic threatening the world, this sort of actions are absolutely unacceptable. We weren't informed before these clinical trials took place despite the fact that patients admitted at NIMS are being monitored by the state government. I have instructed officials to take action if any attempt is made to sell this drug as a potential medicine of Covid-19 in Rajasthan," he said.

(WITH INPUTS FROM
LALMANI VERMA,
LUCKNOW)

Delhi survey

Friday, which must have a healthcare worker to assess a person's medical condition.

"Now, all households in the city will be surveyed by field workers. Till now, we were carrying out surveillance in containment zones and areas where positivity rate was high. Under the revised plan, anyone found with symptoms will be tested," said a senior district official.

A task force comprising representatives of Delhi Police, MCD, district surveillance officials, IT professionals for Aarogya Setu, members from medical colleges and the department of education and youth has to be

ANNEXURE - C-4

Date: 24.06.2020

23

To,
The SHO
PS Vasant Vihar,
New Delhi

Subject: Complaint against Mr. Ram Krishna Yadav @ Yogish
Randev Baba, Mr. Acharya Balkrishna, Mr. Swami Mukta Nanda,
Mr. Swami Shankardev (Trustees of Divya You Mandir Trust) and
Directors of M/S Patanjali Ayurveda Limited

Sir,

I, Tushar Anand, S/o. Dinesh Anand, R/o. A-9/20, Vasant Vihar, New Delhi- 110057. Being constrained to write to you under the circumstances as given below.

That the undersigned on 23.06.2020 came across and watched the above said accused persons on television and on social media claiming that they have developed a medicine namely "Coronil" which 100% cures novel corona virus (Covid-19). That the above named Accused persons in a pre planned hatched conspiracy are taking undue advantage of their public presence/special status in the society and are making claims stating that they have found cure of the said virus. It is pertinent to mention before the authorities that the above named accused persons only had permission to make/produce an immunity booster and they are falsely representing/making a false claim in the media (via press conference) that they have found a cure for the said novel corona virus (covid-19). In my humble opinion the above named accused persons are taking undue advantage of media and have made a false representation to the people who will buy the product since, the above said accused persons are claiming it to cure the said the deadly

corona virus. By virtue of this the above named accused persons in a pre planned hatched conspiracy with malifide intent to cause wrongful loss to the public at large by making such miss-representations and also producing a product for which they never claimed/received a license by the concerned authorities. 24

By virtue of their claims pertaining to the said medicine "Coronil", the above said accused persons have shown their malignancy which is likely to spread infection of disease dangerous to life by misrepresenting & luring their innocent followers to buy the above said medicine with a belief of getting cured from the deadly Novel Coronavirus COVID-19. These false claims have further caused intentional insult with intent to provoke breach of peace among the society at large.

That the above said accused persons are also in violation of AYUSH Ministry's directive of 21.04.2020, as per these directives and conditions it is mandatory for an Institution *"To praise the Ministry of AYUSH, Government of India about the research and developments"*.

That the above said accused persons are in violation of directives against advertisements of false claims of COVID-19 cure. On 24.03.2020, Home Ministry invoked powers under National Disaster Management Act and declared making of false claims with respect of COVID-19 will be a punishable offence. Following this AYUSH Ministry issued directives on 01.04.2020 invoking Section 33(P) of Drugs and Cosmetics Act to stop and prevent publicity and advertisement of AYUSH related claims for COVID-19 treatment in any print, TV, Electronic media and directed the State/UT authorities to take

necessary legal action against the persons/agencies involved found in contravention of the above. 25

That the above said accused persons are also in violation of section 33(E) read with 33(I) of Drugs and Cosmetics Act, 1940 for the offence of "misbranding of Drugs"

That the above said accused are in contravention of Central governments amendment to Drug and Cosmetic Rules, 2012. (i.e, Rule 170) "Diagnosis, cure, mitigation, treatment, or prevention of any disease, disorder, syndrome or condition can not be advertised.


That the above accused are in violation of Drugs and magic Remedies (Objectionable Advertisements Act), 1954. The widespread publicity of the unverified claims of the above said accused persons attracts penal provisions of the same.


It is of utmost importance that a FIR against the above mentioned accused persons be lodged for offences commissioned under section 270/504/120-B/34 of IPC, Drugs and Cosmetics Act, violation of Drug and Cosmetic Rules and Drugs and magic Remedies (Objectionable Advertisements Act), 1954 so that the above said accused persons do not indulge in act of making false representations to public at large and gain money out of the misery of people.

Thanking you,


Tushar Anand
Ph: 8882505047
A6/20 Vasant Vihar, New Delhi

Copy to DCP South West




PST / D
24/6/20

26
ANNEXURE C-5**Complaint against Mr. Ram Krishna Yadav@ Ramdev Baba & others.**

Tushar Anand <anand.tushar93@gmail.com>

24 June 2020 at 20:13

To: dcp.swest@delhipolice.gov.in

Cc: dirdcd@nic.in

Respected Sir,

Kindly find attached my complaint dated 24.06.2020 against Mr. Ram Krishna Yadav @ Ramdev Baba & his accomplices/associates, who have tried to act malignantly to spread infection of Disease (Covid-19) dangerous to life with an intentional insult and intent to provoke breach of peace of the society at large by mis-representing his claims of finding a cure of the deadly coronavirus disease.

The attached complaint is for your kind perusal and directions to the concerned SHO, PS. Vasant Vihar, to register and lodge FIR against the accused persons named in the attached complaint.

The copy of this email is also marked to Shri Mohd. A.T. Ansari (Drug Inspector) and Mr. Swapnil Patil (Drug Inspector) to bring the same to their kind attention and knowledge.

It is requested of your good-selves to kindly acknowledge my email along with the attached scanned copy of complaint received at PS- Vasant Vihar for taking necessary action and directions.

Thank you.

Regards,

Tushar Anand

R/o. A-9/20, Vasant Vihar,

New Delhi - 110057.

Mob. - 8882505047

 tushar ramdev complaint.pdf
891K

Drugs Control Department Delhi <dirdcd@nic.in>

26 June 2020 at 13:18

To: anand tushar93 <anand.tushar93@gmail.com>

Cc: "Sh.devender arya" <dcp.swest@delhipolice.gov.in>

Sir,

The matter in your complaint relate to the department of Ayush as the provision of chapter IV-A of drugs & Cosmetics Act 1940 are not regulated by this department as the product under reference appear to be an Ayurvedic product / Drug.

You are requested to write it to the concern department for taking action action to the department for taking necessary in the matter.


Regards,

Atul Kumar Nasa

Head of Office
Controlling Authority
Drugs Control Department
Govt. of NCT of Delhi
Ph.:011-22393703

27

From: "anand tushar93" <anand.tushar93@gmail.com>
To: "Sh.devender arya" <dcp.swest@delhipolice.gov.in>
Cc: "Drugs Control Department Delhi" <dirdcd@nic.in>
Sent: Wednesday, June 24, 2020 8:13:15 PM
Subject: Complaint against Mr. Ram Krishna Yadav@ Ramdev Baba & others.
[Quoted text hidden]



Tushar Anand <anand.tushar93@gmail.com>
To: Drugs Control Department Delhi <dirdcd@nic.in>
Cc: "Sh.devender arya" <dcp.swest@delhipolice.gov.in>

26 June 2020 at 13:23

Good day sir,
Duly noted with thanks, it would be great if you could mark the concerned department.
So that the said act can be brought to their knowledge and a quick action on the same.

Thank you.

Regards,
Tushar Anand
+8882505047
[Quoted text hidden]

(welfare stamp
not available)



VAKALATNAMA

FIR No.....
U/S.....
P.S. Vasant Vihar

IN THE HON'BLE COURT OF

Ld. CMM, Patiala House Court
AT New Delhi

In the matter of:

Tushar Anand

PETITIONER

VERSUS

State & Ors

RESPONDENT

Know all to whom these presents shall come that I/We
Tushar Anand & Ors. Divesh Anand R/o A9/20 Vasant Vihar
N. Delhi

Them above named the Applicant/complainant do hereby
appoint

LALIT VALECHA (ADV)
ENRL NO. D/1211/2011

MANU PRABHAKAR(ADV)
ENRL NO. D/2785/2012

EVISION LEGAL SOLUTION LLP

S-364, PANCHSHEEL PARK, NEW DELHI 110017

MOBILE NO. 9818770004; EMAIL: EVISIONLLP@GMAIL.COM

Advocate(s), to be my/ our true and lawful attorney (s), in the matter noted above, to do all the following acts, deeds and things, or any of them, (jointly and severally) and also ratify anything already done on our behalf that is to say: -

1. To sign, verify and present and send notices, replies rejoinders, pleadings, appeals, cross-objections or petitions for execution, review, revision, other petitions or affidavit or other documents as shall be deemed necessary or advisable for the prosecution of the case or in relation thereto in all its stages.
2. To appear, act, and plead in the above-mentioned case in any court or tribunal etc, in which the same be heard or tried in the 1st instance or in appeal or review or revision or execution or in any other stage of its progress until its final decision.
3. To withdraw or compromise the said case or submit to arbitration any differences or disputes that may arise to or in any manner relating to the said case.
4. To receive documents, papers, records, orders etc. and to do all other acts all things, which may be necessary or proper to be done for the progress and in all course of the prosecution of the said case.
5. To employ any other legal practitioner, advocate or consultant authorizing him to exercise the power and authority hereby conferred on the Advocate (s) whenever he/they may think fit to do so.

And I/We hereby agree that whatever the Advocate (s) or his/ there substitute shall do in the premises shall be binding on me in all intents and purposes just as if it would have been done by me.

And I/We hereby agree not to hold the Advocate (s) or his/their substitute responsible for the said case in consequence of his absence from the court when the said case is called up for hearing.

And I/We hereby agree that in the event of the whole or any part of the fee agreed by me/ us to be paid to the Advocate (s) remaining unpaid he/they shall be entitled to withdraw from the prosecution of the said case, or not to appear until the same is paid.

In witness whereof I/We hereunto set my/our hand to these presents the contents of which have been explained to and understood by me/us.

Date: 01/07/2020

M. Prabhakar
Adv.

Advocate(s)

Identify
M. Prabhakar

Tushar Anand
Client